# Lactiga

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lactiga

- Industry: Biotechnology
- Headquarters: Toronto, Canada
- Website: www.lactiga.com
- Latest round: Seed (Nov 2, 2020)
- Investors on record: 1

## About

Lactiga, Inc. is a Canadian biotechnology firm specializing in the development of mucosal antibody therapies, specifically targeting secretory Immunoglobulin A (sIgA) derived from human milk to enhance mucosal immunity.Founded in 2017 and headquartered in Toronto, Canada, Lactiga, Inc. focuses on innovative biotherapeutics utilizing maternal antibodies. The company has completed a total of 3 funding deals, with its most recent funding round occurring on February 3, 2025, where it raised USD 1.60 mn led by 1517 Fund. Founders Rik Mehta and Viraj Mane have played pivotal roles in advancing the company's strategic objectives.Lactiga™ specializes in developing innovative mucosal antibody therapies, focusing on secretory Immunoglobulin A (sIgA) antibodies derived from human milk. Their products aim to address health issues such as chronic respiratory disorders, gut inflammation, and immune deficiencies, enhancing mucosal immunity across various systems. Lactiga targets healthcare providers, patients, and medical institutions, particularly in North America and Europe, where there is a demand for advanced immunotherapy solutions.Lactiga generates revenue through direct sales of its proprietary sIgA therapies to healthcare providers and institutions. Transactions typically occur via partnerships with hospitals and clinics, facilitating direct procurement. Revenue may also arise from collaborations with research institutions and pharmaceutical companies. The company's flagship offerings are expected to include one-time sales and potential subscription models for ongoing supply and support.In February 2025, Lactiga, Inc. secured grant funding from the National Institutes of Health and the National Institute of Allergy and Infectious Diseases to advance the development of LCTG-001, the first sIgA mucosally-targeted replacement therapy for patients with compromised immune function. The funding will be utilized to support the design and launch of new products while aiming for geographical expansion into targeted markets in both North America and Europe.

## Funding rounds

- Seed, Nov 2, 2020 — Checkmate Capital

## Investors

- Checkmate Capital (https://capitalatlas.ai/funds/checkmate-capital) — Seed